SEC Company Response from NOVARTIS AG (NVS, NVSEF) (CIK 0001114448) (NVS) — Jul 2, 2013
NOVARTIS AG (NVS, NVSEF) (CIK 0001114448)
Date: July 2, 2013 · CIK: 0001114448 · Accession: 0001104659-13-052843
AI Filing Summary & Sentiment
File numbers found in text: 001-15024
Letter
Form 20-F for Fiscal Year Ended December 31, 2012 Filed January 23, 2013 File No. 001-15024
Re: Novartis AG
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Jonathan Symonds, our former Chief Financial Officer, dated June 19, 2013. As agreed in a recent telephone call between Barry Rosenfeld, of our affiliate Novartis Corporation, and Frank Wyman, Staff Accountant at SEC, we will respond to your letter on or before July 17, 2013.
Respectfully submitted,
Novartis AG
Show Raw Text
CORRESP
1
filename1.htm
Novartis AG
Postfach
4002 Basel
Switzerland
July 2, 2013
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
US Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Re: Novartis AG
Form 20-F for Fiscal Year Ended December 31, 2012
Filed January 23, 2013
File No. 001-15024
Dear Mr. Rosenberg:
We are in receipt of your letter addressed to Jonathan Symonds, our former Chief Financial Officer, dated June 19, 2013. As agreed in a recent telephone call between Barry Rosenfeld, of our affiliate Novartis Corporation, and Frank Wyman, Staff Accountant at SEC, we will respond to your letter on or before July 17, 2013.
Respectfully submitted,
Novartis AG
/s/ HARRY KIRSCH
/s/ FELIX R. EHRAT
Harry Kirsch
Felix R. Ehrat
Chief Financial Officer
General Counsel
Novartis Group
Novartis Group